C4 Therapeutics shareholders approve amendment to 2020 stock incentive plan evergreen provision

• C4 Therapeutics held its annual shareholder meeting on June 24, 2026.
• Shareholders backed the ratification of KPMG as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Investors also adopted an amendment to the 2020 Stock Option and Incentive Plan’s evergreen provision to include outstanding pre-funded warrants in the share count.
• Shareholders also selected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors for terms running to the 2029 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-045194), on June 24, 2026, and is solely responsible for the information contained therein.